Amarin Urges Wider Adoption of Underutilized Cardiovascular Therapies Amid Persistent Treatment Gaps
Event summary
- Amarin calls for urgent adoption of proven cardiovascular therapies during American Heart Month 2026, citing underutilization of FDA- and EMA-approved treatments.
- Nearly half of U.S. adults (48.9%) live with cardiovascular disease, with high-risk patients often failing to achieve LDL-C targets despite available treatments.
- Amarin highlights persistent gaps in prescribing patterns, with many patients untreated or undertreated despite guideline-supported therapies like statins, ezetimibe, PCSK9 inhibitors, and icosapent ethyl.
- The company emphasizes that existing therapies can reduce cardiovascular events today, while future innovations remain years away from clinical outcomes and reimbursement.
The big picture
Amarin's call to action highlights a critical gap in cardiovascular disease prevention, where proven therapies remain underutilized despite their ability to reduce heart attacks and strokes. This underscores a broader industry challenge of translating clinical evidence into real-world practice, particularly in chronic disease management. The company's focus on existing treatments contrasts with the long-term horizon of emerging cardiovascular innovations, emphasizing the need for immediate action to address a leading cause of death.
What we're watching
- Therapy Adoption
- The pace at which healthcare providers and patients adopt proven cardiovascular therapies will determine the impact of Amarin's call to action.
- Regulatory Influence
- Whether regulatory bodies will support broader adoption of existing therapies through policy changes or reimbursement adjustments.
- Market Dynamics
- How Amarin's push for wider therapy utilization affects its market position and competitive landscape in cardiovascular disease treatment.
Related topics